



RADAR – R&D and Adoption Dynamics for Assessment and Response

System dynamics modelling for ex-ante impact assessment of R&I policy

A demonstration project

Igor Oliveira
Bianca Cavicchi

Initiatives at DG R&I




STUDY ON THE EVOLUTION OF THE
FRAMEWORK PROGRAMME FOR
R&I




EXPERT STUDY ON SYSTEM-BASED
METHODS FOR TRANSFORMATIVE
INNOVATION POLICY





TRAINING SYSTEM DYNAMICS
SIMULATION



Strategic Foresight | Agent based modeling (sim)
 Causal Loop Diagrams/ System Mapping | System Dynamics Modeling (sim)









Concrete application of system dynamics in R&I policy ex-ante impact assessment



Build a calibrated model of R&I value chain, from early R&D funding to adoption&diffusion, through tech development, and building impact pathways with competitive sustainability



Identify EU data limitations



Provide strategic reflections for FP10 ex-ante impact assessment

Project objectives

Project scope



Policy

FP for R&I

Transformative
innovation (sustainability
& growth)



Technology

mRNA

Green hydrogen



Geography

Europe (diffusion)


FP countries (R&D)




R&I process

From early stages public
R&D to innovation
diffusion, through
corporate R&D

Common view of R&I evaluation




Expanded view of R&I evaluation



Inputs-Outputs-Outcomes-Impact

Expanded view of R&I evaluation (green hydrogen)



Key assumptions



This is only one among many possible representations of an innovation system. Accumulation of systemic capabilities (e.g., support orgs) is not considered



FP process stays stable (budgeting, project selection, disbursement) but focus across value chains can vary



Macroeconomic conditions stay stable, apart from the impact of these specific technologies and cost of capital variations defined by the user of the model



Contribution of non-EC players to R&D pipelines kept constant across all scenarios



Human capital availability considered unconstrained when companies re-invest or increase installed capacity




Apart from covid, drugs for other diseases are developed according to current industry pipeline



Diminishing returns of drug development technology

The view represented in the model (green hydrogen)



Datasets in use


European Commission

- FP funding and number of projects over time
- Share of public/private co-publications
- Project duration
- Intellectual Property Products (IPRs – publications, methods, processes, patents) - **calibration**
- Pipeline ratios (e.g., contribution of IPRs to capital goods and drug development technology) computed from all related projects
- BERD by industry orientation (re-investment into hydrogen R&D)
- Sub-domain focus of the FP within hydrogen (monitoring flash)
- EIB loans (disbursements, interest and repayments)
- EU procurement of vaccines (\$, units)
- Historical and planned European Hydrogen Bank subsidies
- Hydrogen cost curves from EU reference scenario - **calibration**



Corporate

- Financial data from 5 pharma companies that have financial ties with the EU (margin, cash generation, reinvestment rates into R&D)
- Some of the R&D pipeline success rates and delays (others had to be calibrated)
- mRNA drugs released over time - **calibration**
- Historical and projected green hydrogen capacity and adoption (Hydrogen Europe) - **calibration**

Calibration (and fit to future projections)




- Effect of green hydrogen technology on electrolysis and production site storage cost
- Average conversion investment cost as relative to 2020
- Average conversion O&M cost as relative to 2015



Considering the relatively small financial effort compared to overall R&D expenditure, and considering that the FP focuses on upstream research, it would be reasonable to assume it doesn't move the needle of clean energy adoption in Europe...


Figure 2.1-7 The contribution of the Framework Programme for R&I as a percentage of total and public R&D expenditure, 2018-2021



Science, research and innovation performance of the EU 2024

Source: DG Research and Innovation, Common R&I Strategy and Foresight Service, Chief Economist Unit's own elaboration based on Eurostat.

From DG R&I (2024)



Sources: Estimated from IEA (2023) by assuming the share of EU27 investment in the world total is equal to its share of world GDP. EU budget figures from European Commission (2024), annualised by dividing grand total by the duration of the multiannual funding framework.

Figure 2 - EU support (overall) and public and private investment on clean energy in EU27 member states (approx.), 2023, in billion EUR



From Pontikakis et al. (2024)

... however, that is not what our simulations show for the green hydrogen domain



We identified two different systemic roles for the FP:

- 1. Foundational role:** the upstream contribution of the FP in the R&I process is key to ensure adoption
- 2. Synergistic role:** in the context of broader policy-induced transformation, the FP magnifies the positive outcomes and impacts of other measures

Foundational role: the FP creates conditions for technologies to be adopted



Synergistic role: the FP helps broader policy packages to move the tech adoption needle




BUT...


1. When we expand model boundaries, we also create the need for datasets that don't exist
- 

BUT...

1. When we expand model boundaries, we also create the need for datasets that don't exist




Pharma companies disclose the development stage of each drug they're developing and what disease(s) they tackle




There isn't an equivalent dataset in the green hydrogen domain

BUT...

1. When we expand model boundaries, we also create the need for datasets that don't exist



Among the Intellectual Property Rights (IPRs) reported as outputs of FP projects, there are some instances of 'products'




However, there is an ontological difference between this and the use of the word 'product' by industry players

BUT...


1. When we expand model boundaries, we also create the need for datasets that don't exist
2. To really understand impact pathways as measured by SDGs and other frameworks, we need a multi-scale modelling approach
 - Contrary to the original nature of these indicators, what we manage to measure is often the relative contribution of these very specific technological domains
 - Contrary to the original nature of these indicators, we don't capture national policy

SDG indicators


Contribution to "9.2.1 Manufacturing value added per capita"



"Avoided 9.4.1 CO2 emission per unit of value added"



SDG indicators



Key policy messages



The FP synergises with other policy mechanisms in creating competitiveness and sustainable development



Funding decision depends on maturity of value chain components and research landscape: for mRNA downstream public research, for green hydrogen core tech private research



Major impact of regulations, cost of capital and collaboration



Deployment (including pioneer installed capacity) is also innovation, so deployment support is also innovation policy

Thank you



© European Union 2023

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Slide xx: [element concerned](#), source: [e.g. Fotolia.com](#); Slide xx: [element concerned](#), source: [e.g. iStock.com](#)